Combination Therapy Synergies for CBS/PSP

Combination Therapy Synergies for CBS/PSP

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Combination Therapy Synergies for CBS/PSP</th>
</tr>
<tr>
<td class="label">Drug A</td>
<td>Drug B</td>
</tr>
<tr>
<td class="label">Rasagiline</td>
<td>Lithium</td>
</tr>
<tr>
<td class="label">Rasagiline</td>
<td>Tramadol, meperidine</td>
</tr>
<tr>
<td class="label">Levodopa</td>
<td>Antipsychotics (except clozapine/quetiapine)</td>
</tr>
<tr>
<td class="label">Levodopa</td>
<td>MAO-B inhibitors (rasagiline, safinamide)</td>
</tr>
<tr>
<td class="label">CoQ10</td>
<td>Warfarin</td>
</tr>
<tr>
<td class="label">Vitamin K antagonists</td>
<td>Aspirin/NSAIDs</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Combination</td>
</tr>
<tr>
<td class="label">TauX Combination</td>
<td>Anti-tau + Anti-inflammatory</td>
</tr>
<tr>
<td class="label">LILLY Combo</td>
<td>Donanemab + GLP-1 agonist</td>
</tr>
<tr>
<td class="label">Synaptic Combo</td>
<td>BDNF + Anti-amyloid</td>
</tr>
<tr>
<td class="label">Anti-Tau + GLP-1 (Proposed)</td>
<td>E2814/Bepranemab + Tirzepatide/Semaglutide</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Score</td>
</tr>
<tr>
<td class="label">Mechanistic Rationale</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Preclinical Evidence</td>
<td>6/10</td>
</tr>
<tr>
<td class="label">Clinical Evid

Combination Therapy Synergies for CBS/PSP

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Combination Therapy Synergies for CBS/PSP</th>
</tr>
<tr>
<td class="label">Drug A</td>
<td>Drug B</td>
</tr>
<tr>
<td class="label">Rasagiline</td>
<td>Lithium</td>
</tr>
<tr>
<td class="label">Rasagiline</td>
<td>Tramadol, meperidine</td>
</tr>
<tr>
<td class="label">Levodopa</td>
<td>Antipsychotics (except clozapine/quetiapine)</td>
</tr>
<tr>
<td class="label">Levodopa</td>
<td>MAO-B inhibitors (rasagiline, safinamide)</td>
</tr>
<tr>
<td class="label">CoQ10</td>
<td>Warfarin</td>
</tr>
<tr>
<td class="label">Vitamin K antagonists</td>
<td>Aspirin/NSAIDs</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Combination</td>
</tr>
<tr>
<td class="label">TauX Combination</td>
<td>Anti-tau + Anti-inflammatory</td>
</tr>
<tr>
<td class="label">LILLY Combo</td>
<td>Donanemab + GLP-1 agonist</td>
</tr>
<tr>
<td class="label">Synaptic Combo</td>
<td>BDNF + Anti-amyloid</td>
</tr>
<tr>
<td class="label">Anti-Tau + GLP-1 (Proposed)</td>
<td>E2814/Bepranemab + Tirzepatide/Semaglutide</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Score</td>
</tr>
<tr>
<td class="label">Mechanistic Rationale</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Preclinical Evidence</td>
<td>6/10</td>
</tr>
<tr>
<td class="label">Clinical Evidence</td>
<td>5/10</td>
</tr>
<tr>
<td class="label">Safety Profile</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">Accessibility</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Patient Fit</td>
<td>8/10</td>
</tr>
</table>

Combination therapy — the simultaneous use of two or[@rochfort2023] more therapeutic agents targeting different pathological pathways — is particularly relevant for [corticobasal syndrome](/diseases/corticobasal-syndrome) (CBS) and [progressive supranuclear palsy](/diseases/progressive-supranuclear-palsy) (PSP), collectively referred to as atypical parkinsonism or 4R-tauopathies. These conditions involve multiple concurrent pathological mechanisms including tau protein aggregation, neuroinflammation, mitochondrial dysfunction, and synaptic loss.[@kaur2023]

This page provides a comprehensive analysis of evidence-based combination strategies for CBS/PSP patients, with particular focus on synergistic drug combinations, multi-target network pharmacology approaches, and sequential therapy protocols for this patient population.[@simmons2023]

Rationale for Combination Therapy in CBS/PSP

Multifactorial 4R-Tauopathy Biology

CBS and PSP are characterized by the aggregation of 4-repeat tau isoforms, but the disease process involves multiple interacting pathological mechanisms:

• [Tau pathology](/mechanisms/tau-pathology): 4R-tau filament formation, oligomerization, and spreading via prion-like mechanisms
• [Neuroinflammation](/mechanisms/neuroinflammation-psp): Chronic microglial activation, complement system activation, and cytokine-mediated neurotoxicity
• [Mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction): Energy deficit, ROS production, and mitophagy impairment
• [Synaptic dysfunction](/mechanisms/synaptic-loss): Dendritic spine loss, neurotransmitter deficits, and network disconnection
• [Blood-brain barrier dysfunction](/mechanisms/bbb-dysfunction-pathway): Neurovascular unit compromise and impaired drug delivery
• [Oxidative stress](/mechanisms/oxidative-stress): Lipid peroxidation, protein oxidation, and DNA damage

Lessons from Adjacent Fields

The success of combination therapy in other therapeutic areas provides a strong rationale for CBS/PSP:

• Oncology: Cancer therapy evolved from single-agent chemotherapy to rational combinations based on molecular profiling. Similarly, biomarker-guided patient stratification enables personalized combination selection for tauopathy patients.
• Infectious disease: HAART (triple antiretroviral therapy) transformed HIV from fatal to manageable. Analogously, combination neuroprotection targets multiple cell death pathways simultaneously.
• Cardiovascular: Multi-drug regimens for hypertension and heart failure demonstrate the value of attacking multiple mechanisms.

Pharmacological Synergy Types

Combination therapy can produce three types of interaction:

Evidence-Based Combination Strategies for CBS/PSP

1. Anti-Tau + Anti-Inflammatory Combinations

Rationale: Neuroinflammation accelerates tau pathology, and tau clearance requires functional, non-hyper-activated microglia. This combination addresses both the pathological protein and the inflammatory environment that promotes its spread.

Combination A: Anti-Tau Antibody + TREM2 Modulator

• Components: [E2814](/clinical-trials/e2814) or [bepranemab](/clinical-trials/bepranemab) + AL002 or AL003
• Mechanism: Anti-tau antibodies clear extracellular and intracellular tau; TREM2 agonists enhance microglial phagocytosis while promoting the disease-associated microglia (DAM) phenotype that supports tau clearance
• Evidence: Preclinical studies show TREM2 activation enhances anti-tau antibody efficacy in mouse models
• Clinical status: Both E2814 (NCT05615614 (DOES NOT EXIST)) and AL002 are in clinical development; combination trials planned

Combination B: Anti-Tau Antibody + CSF1R Inhibitor

• Components: Anti-tau antibody + PLX5622 or pexidartinib
• Mechanism: CSF1R inhibition reduces microglial proliferation and pro-inflammatory signaling while allowing anti-tau antibodies to engage remaining functional microglia
• Evidence: PLX5622 shows reduced neuroinflammation and improved tau clearance in preclinical models
• Clinical status: CSF1R inhibitors in Phase 1/2; combination approaches in development

Combination C: Tau Aggregation Inhibitor + Anti-Inflammatory

• Components: [Lithium](/therapeutics/lithium-neurodegeneration) or [Methylene blue](/therapeutics/methylene-blue-tauopathy) + Minocycline or Rapamycin
• Mechanism: Tau aggregation inhibitors reduce tau oligomerization; anti-inflammatory agents reduce cytokine-mediated tau phosphorylation and spreading
• Evidence: Lithium shows neuroprotective effects in tauopathy models; combination may reduce disease progression
• Caution: Lithium is contraindicated with MAO-B inhibitors (rasagiline) due to serotonin syndrome risk

Combination D: Anti-Tau Antibody + Lithium

• Components: Anti-tau antibody ([E2814](/clinical-trials/e2814), [bepranemab](/clinical-trials/bepranemab), or [semorinemab](/therapeutics/semorinemab)) + [Low-dose lithium carbonate](/therapeutics/lithium-tauopathy)
• Mechanism: Dual targeting of tau pathology through orthogonal mechanisms — anti-tau antibodies clear extracellular and spreading tau species while lithium reduces tau phosphorylation via GSK3β inhibition and enhances autophagy via IMPase inhibition
• Rationale: Lithium's multi-pathway effects (GSK3β inhibition, autophagy enhancement, neurotrophic support) complement anti-tau antibody-mediated clearance. Preclinical studies suggest lithium may enhance microglial function for better antibody-mediated tau clearance.
• Dosing rationale:
• Anti-tau antibody: Standard dosing per specific agent (e.g., E2814 IV monthly per NCT05615614 (DOES NOT EXIST) protocol)
• Lithium: Low-dose approach targeting serum level 0.3-0.6 mEq/L (microdose to low therapeutic range)
• Sequential or concurrent administration: Preclinical data suggests concurrent is acceptable; stagger infusion timing to minimize interaction risk
• Proposed trial design: Phase 2 randomized, placebo-controlled factorial design evaluating anti-tau antibody + lithium vs anti-tau antibody alone vs lithium alone vs placebo. 12-18 month duration with adaptive sample size.
• Biomarker endpoints: CSF p-tau181/217 reduction (primary), tau PET signal change (secondary), plasma NfL trajectory, CSF total tau
• Safety monitoring: Enhanced lithium safety protocol — baseline renal/thyroid, weekly levels for first month, biweekly months 2-3, monthly thereafter; interaction monitoring with anti-tau infusion reactions
• Clinical status: Preclinical rationale strong; no current combination trials registered — opportunity for academic consortium or pharma partnership

1b. Anti-Tau + GLP-1 Agonist Combinations (HIGH PRIORITY)

Rationale: Combining anti-tau immunotherapy with GLP-1 receptor agonists addresses both the core pathological protein (4R-tau aggregation) AND creates a neuroprotective metabolic milieu. GLP-1 agonists provide anti-inflammatory effects, improved cerebral glucose metabolism, enhanced mitochondrial function, and reduced oxidative stress — all of which may enhance the efficacy of tau clearance.

Combination A: Anti-Tau Antibody + GLP-1 Agonist

• Components: [E2814](/clinical-trials/e2814), [Bepranemab](/clinical-trials/bepranemab), or [Semorinemab](/therapeutics/semorinemab) + [Tirzepatide](/therapeutics/tirzepatide-dual-gip-glp-agonists-neurodegeneration), [Semaglutide](/therapeutics/semaglutide-neurodegeneration), or [Lixisenatide](/therapeutics/lixisenatide-neurodegeneration)
• Mechanism: Dual disease-modifying approach:
• Anti-tau antibodies: Clear extracellular and intracellular tau aggregates, block spreading
• GLP-1 agonists: Reduce neuroinflammation via microglia modulation, improve cerebral glucose metabolism, enhance mitochondrial ATP production, reduce oxidative stress, promote autophagy
• Rationale: The neuroprotective milieu created by GLP-1 signaling may enhance microglial function for better antibody-mediated tau clearance, while anti-tau immunotherapy removes the pathological substrate
• Evidence:
• Lixisenatide showed motor stabilization in PD Phase 2 trial (p=0.007)
• Tirzepatide in Phase 2 for AD/PD (dual GIP/GLP-1 provides enhanced neuroprotection)
• Semaglutide completed MOST-ABLE Phase 2 (AD) with brain volume preservation
• Anti-tau immunotherapies (E2814, Bepranemab) showing 33-58% tau slowing in Phase 2
• Preclinical: GLP-1 signaling enhances microglial phagocytosis of tau aggregates
• Dosing rationale:
• Anti-tau antibody: Standard protocol (e.g., E2814 IV monthly per NCT05615614 (DOES NOT EXIST))
• GLP-1 agonist: Low-dose initiation with titration (semaglutide 0.25mg weekly → 0.5mg → 1.0mg)
• Timing: Can be initiated concurrently; stagger infusion timing if concerns about compounding infusion reactions
• Proposed trial design: Phase 2/3 randomized factorial — anti-tau + GLP-1 vs anti-tau alone vs GLP-1 alone vs placebo. 18-24 month duration. Primary: CBS/PSP rating scale (PSPRS), secondary: tau PET, plasma NfL, p-tau217
• Safety profile: Favorable for both classes — anti-tau: ARIA-E, infusion reactions; GLP-1: GI symptoms (nausea), pancreatitis risk. Combined monitoring recommended
• Clinical status: No registered tauopathy combination trials yet. LILLY Combo trial (NCT05642311) evaluates Donanemab + GLP-1 agonist in AD, providing a template. Major opportunity for pharma/academic partnership

Combination B: Anti-Tau Antibody + Dual GIP/GLP-1 Agonist

• Components: Anti-tau antibody + [Tirzepatide](/therapeutics/tirzepatide-dual-gip-glp-agonists-neurodegeneration) or [Retatrutide](/therapeutics/retatrutide-triple-agonist-neurodegeneration)
• Mechanism: Enhanced neuroprotection through multiple incretin receptors — dual/triple agonist provides:
• GIP receptor signaling: Additive anti-inflammatory effects, potential amyloid/tau modulation
• GLP-1 receptor signaling: Neuroprotection, mitochondrial function
• (Retatrutide adds) FGF21: Metabolic stress resistance, mitochondrial quality control
• Evidence: Tirzepatide in Phase 2 for AD/PD; Retatrutide in Phase 1/2 with strong preclinical data
• Clinical status: Individual agents advancing; combination trials needed

Combination C: Tau Aggregation Inhibitor + GLP-1 Agonist

• Components: [Lithium](/therapeutics/lithium-neurodegeneration) or [Methylene blue](/therapeutics/methylene-blue-tauopathy) + [Semaglutide](/therapeutics/semaglutide-neurodegeneration) or [Lixisenatide](/therapeutics/lixisenatide-neurodegeneration)
• Mechanism: Lithium reduces tau phosphorylation via GSK3β inhibition; GLP-1 agonists provide complementary neuroprotection. Note: Lithium is CONTRAINDICATED with rasagiline (MAO-B inhibitor) — patient should not use this combination
• Evidence: Both classes show neuroprotective effects in preclinical models
• Caution: Lithium + rasagiline = SEROTONIN SYNDROME RISK — do not combine in current patient regimen

Combination D: GLP-1 Agonist + Autophagy Enhancer

• Components: GLP-1 agonist ([Tirzepatide](/therapeutics/tirzepatide-dual-gip-glp-agonists-neurodegeneration) or [Semaglutide](/therapeutics/semaglutide-neurodegeneration)) + [Rapamycin](/therapeutics/rapamycin-mtor-inhibition-neurodegeneration) or [Urolithin A](/therapeutics/urolithin-a-mitophagy) or Trehalose
• Mechanism: Complementary autophagy enhancement — GLP-1 agonists enhance macroautophagy through mTOR-independent pathways; rapamycin/trehalose enhance through mTOR inhibition. Combined effect: synergistic clearance of tau aggregates and damaged mitochondria
• Evidence: Both classes show neuroprotection in preclinical models
• Clinical status: Individual agents in trials; combination approaches proposed

2. Mitochondrial + Neuroprotective Combinations

Rationale: Mitochondrial dysfunction is a central feature of 4R-tauopathies. Combining mitochondrial support with broad neuroprotection addresses energy deficit and oxidative stress simultaneously.

Combination A: CoQ10 + Vitamin E Analogs

• Components: [CoQ10](/therapeutics/coenzyme-q10-neurodegeneration) + [EUK-134](/therapeutics/euk-134-superoxide-dismutase) or [MitoQ](/therapeutics/mitoq-mitochondrial-antioxidant)
• Mechanism: CoQ10 supports electron transport chain and ATP production; EUK-134 scavenges superoxide radicals; both address different aspects of oxidative stress
• Evidence: CoQ10 showed promise in Phase 2 PSP trials; combinations with other antioxidants under investigation
• Dosing: CoQ10 300-600 mg/day; EUK-134 20-40 mg/day

Combination B: PGC-1α Activator + NAD+ Precursor

• Components: [Pioglitazone](/therapeutics/pioglitazone-ppar-agonist-neurodegeneration) or [Resveratrol](/therapeutics/resveratrol-sirtuin-activator) + [NMN](/therapeutics/nicotinamide-mononucleotide-nmn) or [NR](/therapeutics/nicotinamide-riboside-nr)
• Mechanism: PGC-1α activation promotes mitochondrial biogenesis; NAD+ precursors support sirtuin function and mitochondrial dynamics
• Evidence: Preclinical data shows synergistic benefits in neurodegeneration models
• Clinical status: NAD+ precursors in clinical trials for neurodegeneration; combination approaches in development

Combination C: Mitochondrial Biogenesis + Autophagy Enhancement

• Components: [Urolithin A](/therapeutics/urolithin-a-mitophagy) + [Rapamycin](/therapeutics/rapamycin-mtor-inhibition-neurodegeneration) or Trehalose
• Mechanism: Urolithin A promotes mitophagy; rapamycin/trehalose enhance macroautophagy; combined effect clears damaged mitochondria and protein aggregates
• Evidence: Urolithin A improved mitochondrial function in Phase 2 PD trials; rapamycin shows promise in tauopathy models
• Caution: Rapamycin may interact with immunosuppressive effects; monitor for infections

3. Neurotrophic Factor + Neuroprotective Combinations

Rationale: Supporting neuronal survival and function while promoting resilience to tau pathology.

Combination A: GLP-1 Agonist + Neurotrophin

• Components: [Semaglutide](/therapeutics/semaglutide-glp1-agonist) or [Exenatide](/therapeutics/exenatide-glp1-agonist) + [BDNF](/therapeutics/bdnf-neurotrophin-therapy) mimetic
• Mechanism: GLP-1 agonists provide metabolic support and reduce neuroinflammation; BDNF mimetics support synaptic plasticity and neuronal resilience
• Evidence: Exenatide showed motor benefits in PD trials; GLP-1 agonists in Phase 3 for AD
• Clinical status: GLP-1 agonists in clinical trials for tauopathies; BDNF mimetics in development

Combination B: GDNF/CDNF + Anti-Apoptotic

• Components: AAV-GDNF or AAV-CDNF gene therapy + [Bcl-2](/therapeutics/bcl2-family-therapeutics) modulator
• Mechanism: GDNF/CDNF provide trophic support to dopaminergic neurons; Bcl-2 modulators prevent apoptosis
• Evidence: AAV-GDNF in clinical trials for PD; applicability to CBS/PSP under investigation
• Delivery: Requires neurosurgical delivery (intraparenchymal or convection-enhanced)

4. Symptomatic + Disease-Modifying Combinations

Rationale: Maintain symptom control while addressing underlying disease pathology.

Combination A: Levodopa + Disease-Modifying Agent

• Components: [Levodopa](/therapeutics/levodopa-carbidopa) + [Inosine](/therapeutics/inosine-urate-neuroprotection) or [CoQ10](/therapeutics/coenzyme-q10-neurodegeneration)
• Mechanism: Levodopa provides symptomatic relief; urate or CoQ10 may provide disease-modifying benefits through antioxidant and mitochondrial mechanisms
• Evidence: SINO trial showed urate safety in PD; CoQ10 showed benefit in PSP
• Current regimen: Patient currently on levodopa + rasagiline; adding disease-modifying agents should be done with monitoring

Combination B: MAO-B Inhibitor + Neuroprotective

• Components: [Rasagiline](/therapeutics/rasagiline-mao-b-inhibitor) + [Sulforaphane](/therapeutics/sulforaphane-nrf2-activator) or [Vitamin D](/therapeutics/vitamin-d-neuroprotection)
• Mechanism: Rasagiline provides symptomatic benefit through MAO-B inhibition and可能有 neuroprotective properties; sulforaphane activates NRF2 antioxidant response
• Evidence: Rasagiline approved for PD; sulforaphane shows neuroprotective potential
• Caution: Avoid combining lithium with rasagiline due to serotonin syndrome risk

5. Multi-Target Network Pharmacology Combinations

Rationale: Using computational approaches to identify optimal drug combinations targeting multiple disease-relevant pathways.

Combination A: Network-Based Multi-Target

• Components: Selected based on patient-specific omics profile
• Approach: Single-cell transcriptomics from patient-derived neurons or induced pluripotent stem cells (iPSC) can guide combination selection
• Evidence: 2025 Cell publication demonstrated computational combination design for AD using integrated multi-omics
• Application: Could be applied to CBS/PSP using patient-specific iPSC-derived neurons

Combination B: Multi-Pathway Targeting

• Components: [Pioglitazone](/therapeutics/pioglitazone-ppar-agonist-neurodegeneration) (PPAR-γ) + [Minocycline](/therapeutics/minocycline-tetracycline-neuroprotection) (neuroinflammation) + [Memantine](/therapeutics/memantine-nmda-antagonist) (excitotoxicity)
• Mechanism: Each agent targets a distinct pathway; combined effect addresses neuroinflammation, excitotoxicity, and metabolic dysfunction
• Evidence: Individual agents show safety in neurodegeneration; combination requires further validation

Sequential Therapy Protocols

Sequential therapy involves strategically sequencing treatments to maximize benefit while minimizing risks.

Phase 1: Stabilization (Months 1-3)

• Continue current levodopa regimen; optimize dosing
• Initiate neuroprotective supplements (CoQ10, vitamin D, omega-3)
• Establish biomarker baseline (NfL, p-tau217, MRI)

Phase 2: Enhancement (Months 4-12)

• PRIORITY: Consider GLP-1 agonist — Lixisenatide (strongest PD data, p=0.007), Tirzepatide (dual GIP/GLP-1, Phase 2 for AD/PD), or Semaglutide (oral option, completed MOST-ABLE)
• If anti-tau immunotherapy becomes available (E2814, Bepranemab trials): Consider combination with GLP-1 agonist for synergistic effect
• Add targeted anti-inflammatory (if compatible with current regimen)
• Initiate physical therapy and lifestyle interventions

Phase 3: Intensification (Year 2+)

• Evaluate for clinical trial participation (anti-tau + GLP-1 combination trials)
• Consider combination approaches with higher evidence level
• Monitor for emerging therapies (anti-tau immunotherapies, gene therapy)

Sequential Protocol for Rapid Progressors

Safety Considerations and Drug Interaction Matrix

Critical Drug Interactions for CBS/PSP Patients

Combination Safety Monitoring

Clinical Trial Landscape for Combination Approaches

Active Combination Trials in Tauopathies

Planned/Proposed Combinations

• Anti-tau antibody + CSF1R inhibitor
• Anti-tau antibody + GLP-1 agonist (HIGH PRIORITY) — E2814 + Tirzepatide/Semaglutide for CBS/PSP
• GLP-1 agonist + NAD+ precursor
• Senolytic (D+Q) + Anti-tau therapy

Patient-Specific Recommendations

For the current patient (50-year-old male, CBS/PSP, DAT scan confirmed, on levodopa + rasagiline):

Immediate Actions

Near-Term (3-6 months)

• Lixisenatide (strongest motor benefit signal in PD, p=0.007) — 5µg BID subQ → 10µg BID
• Tirzepatide (dual GIP/GLP-1, Phase 2 for AD/PD) — 2.5mg weekly → 5mg weekly
• Semaglutide (oral option available) — 0.25mg weekly → 0.5mg → 1.0mg

Long-Term (12+ months)

Cross-Links to Related Pages

• [Personalized Treatment Plan](/therapeutics/personalized-treatment-plan-atypical-parkinsonism) - Main treatment hub
• [Anti-Tau Immunotherapies](/therapeutics/tau-targeted-therapeutics) - E2814, bepranemab
• [GLP-1 Receptor Agonists](/therapeutics/glp1-receptor-agonists) - Semaglutide, exenatide
• [Mitochondrial Therapeutics](/therapeutics/mitochondrial-therapies-neurodegeneration) - CoQ10, MitoQ, urolithin A
• [Neuroinflammation in PSP](/mechanisms/neuroinflammation-psp) - Target pathway
• [CSF1R Inhibitors](/therapeutics/csf1r-inhibitors-neurodegeneration) - PLX5622, pexidartinib
• [Clinical Trials](/clinical-trials/drug-pipeline) - Current trial landscape

NET Assessment

Network Evidence Translational (NET) Score: 42/60 (70%)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
• [TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: TREM2
• [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF
• [Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: GLP1R, BDNF
• [TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypothesis/h-044ee057) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: TREM2
• [Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — <span style="color:#ffd54f;font-weight:600">0.48</span> · Target: CHR2/BDNF
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST

• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;
• [Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) &#x1f504;
• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014) &#x1f504;